Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Jul 1;29(3):154-161.
doi: 10.4078/jrd.2022.29.3.154.

Modified Body Mass Index at Diagnosis is a Useful Predictor of Mortality in Patients With Antineutrophil Cytoplasmic Antibody-associated Vasculitis

Jung Yoon Pyo  1 , Sung Soo Ahn  1 , Jason Jungsik Song  1   2 , Yong-Beom Park  1   2 , Sang-Won Lee  1   2
Affiliations

Modified Body Mass Index at Diagnosis is a Useful Predictor of Mortality in Patients With Antineutrophil Cytoplasmic Antibody-associated Vasculitis

Jung Yoon Pyo et al. J Rheum Dis. .

Abstract

Objective: We investigated whether modified body mass index (mBMI) at diagnosis could predict all-cause mortality during follow-up in patients with antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV).

Methods: The medical records of 203 AAV patients with BMI ≥18.5 kg/m2 were reviewed. mBMI was calculated using an equation mBMI=BMI (kg/m2)×serum albumin (g/L). All-cause mortality was considered as a poor outcome, and the follow-up duration based on all-cause mortality was defined as the period from AAV diagnosis to death for deceased patients, and the period from AAV diagnosis to the last visit for surviving patients.

Results: The median age was 59.0 years (35.5% were male). The median BMI and mBMI were 22.8 kg/m2 and 813.2 kg · g/m2 · L. Twenty-five patients (12.3%) died. mBMI was well correlated with age, BVAS, FFS, erythrocyte sedimentation rate and C-reactive protein at diagnosis. Deceased patients exhibited significantly lower mBMI at diagnosis compared to surviving patients. AAV patients mBMI ≤570.1 kg · g/m2 · L showed a significantly higher frequency of all-cause mortality (38.5% vs. 8.5%), and furthermore, exhibited a significantly higher risk for all-cause mortality than those with mBMI >570.1 kg · g/m2 · L (RR 6.750). mBMI ≤570.1 kg · g/m2 · L showed a significantly lower cumulative patients' survival rate than those with mBMI >570.1 kg · g/m2 · L. In the multivariable Cox hazards model analysis, either serum albumin or mBMI was significantly associated with all-cause mortality in AAV patients.

Conclusion: In conclusion, mBMI ≤570.1 kg · g/m2 · L at diagnosis may be a useful predictor of all-cause mortality during follow-up additionally to serum albumin in AAV patients.

Keywords: Albumin; Antineutrophil cytoplasmic antibody; Body mass index; Mortality.

PubMed Disclaimer

Conflict of interest statement

CONFLICT OF INTEREST No potential conflict of interest relevant to this article was reported.

Figures

Fig. 1
Fig. 1
Comparison between surviving and deceased patients. (A) BMI at diagnosis did not differ between the two groups. (B, C) However, deceased patients exhibited significantly lower serum albumin and mBMI at diagnosis. mBMI: modified body mass index, BMI: body mass index, AAV: ANCA-associated vasculitis, ANCA: antineutrophil cytoplasmic antibody.
Fig. 2
Fig. 2
(A) When the cut-offs of mBMI for all-cause mortality were obtained using the ROC curve (area 0.702, 95% CI 0.598~0.807), mBMI of 570.1 was chosen for the optimal one due to the maximised sum of sensitivity and specificity. All-cause mortality was identified more frequently in AAV patients with mBMI ≤570.1 kg · g/m2 · L than those without. (B) Furthermore, AAV patients with mBMI ≤570.1 kg · g/m2 · L exhibited a significantly higher risk for all-cause mortality than those without. mBMI: modified body mass index, ROC: the receiver operator characteristic, CI: confidence interval, AAV: ANCA-associated vasculitis, ANCA: antineutrophil cytoplasmic antibody, RR: relative risk.
Fig. 3
Fig. 3
AAV patients with mBMI ≤570.1 kg · g/m2 · L showed a significantly lower cumulative patients’ survival rate than those without. AAV: ANCA-associated vasculitis, ANCA: antineutrophil cytoplasmic antibody, mBMI: modified body mass index.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Jennette JC, Falk RJ, Bacon PA, Basu N, Cid MC, Ferrario F, et al. 2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. Arthritis Rheum. 2013;65:1–11. doi: 10.1002/art.37715. - DOI - PubMed
    1. Watts R, Lane S, Hanslik T, Hauser T, Hellmich B, Koldingsnes W, et al. Development and validation of a consensus methodology for the classification of the ANCA-associated vasculitides and polyarteritis nodosa for epidemiological studies. Ann Rheum Dis. 2007;66:222–7. doi: 10.1136/ard.2006.054593. - DOI - PMC - PubMed
    1. Schönermarck U, Gross WL, de Groot K. Treatment of ANCA-associated vasculitis. Nat Rev Nephrol. 2014;10:25–36. doi: 10.1038/nrneph.2013.225. - DOI - PubMed
    1. Flossmann O, Berden A, de Groot K, Hagen C, Harper L, Heijl C, et al. Long-term patient survival in ANCA-associated vasculitis. Ann Rheum Dis. 2011;70:488–94. doi: 10.1136/ard.2010.137778. - DOI - PubMed
    1. Choi CB, Park YB, Lee SW. Antineutrophil cytoplasmic antibody-associated vasculitis in Korea: a narrative review. Yonsei Med J. 2019;60:10–21. doi: 10.3349/ymj.2019.60.1.10. - DOI - PMC - PubMed

LinkOut - more resources